# ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

> **NCT02688712** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Providence Health & Services** · enrollment: 50 (estimated)

## Conditions studied

- Rectal Adenocarcinoma

## Interventions

- **DRUG:** LY2157299
- **DRUG:** Capecitabine
- **DRUG:** Fluorouracil
- **PROCEDURE:** Tumor specific mesorectal excision

## Key facts

- **NCT ID:** NCT02688712
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-03-24
- **Primary completion:** 2026-01-26
- **Final completion:** 2026-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02688712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02688712, "ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02688712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*